Indian Drug Makers Wooed By Pfizer Of U.S. For Alliances
This article was originally published in PharmAsia News
Several Indian drug makers are being contacted by U.S.-based Pfizer seeking alliances with generics makers as the U.S. company faces expiration of patents for some of its major drugs
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
The Environmental Working Group and US PIRG suggest that beauty and personal-care firms should avoid using talc in loose powders, if not all cosmetic products, and that the US FDA should consider banning the ingredient due to the potential for asbestos contamination, among other concerns.
When businesses rapidly pivot to offering consumer health products and services, they’re likely not contemplating compliance with FDA regulations. Recent warning letters are more proof COVID-19 represents opportunities for numerous businesses that aren’t prepared to follow or simply aren’t aware of FDA regulations.